Bangkok Genomics Innovation Pcl
Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand; preimplantation chromosomal abnormality and thalassemia carrier gene screening; infectious disease group analysis; testing for human papilloma virus; and monkeypox virus, COVID… Read more
Bangkok Genomics Innovation Pcl (BKGI) - Total Liabilities
Latest total liabilities as of September 2024: ฿66.43 Million THB
Based on the latest financial reports, Bangkok Genomics Innovation Pcl (BKGI) has total liabilities worth ฿66.43 Million THB as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bangkok Genomics Innovation Pcl - Total Liabilities Trend (2018–2023)
This chart illustrates how Bangkok Genomics Innovation Pcl's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bangkok Genomics Innovation Pcl Competitors by Total Liabilities
The table below lists competitors of Bangkok Genomics Innovation Pcl ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Emova Group SA
PA:ALEMV
|
France | €42.01 Million |
|
Foodlink A.E
AT:FOODL
|
Greece | €48.09 Million |
|
Eumundi Group Ltd
AU:EBG
|
Australia | AU$39.91 Million |
|
Polarean Imaging plc
PINK:PLLWF
|
USA | $3.19 Million |
|
PlexBio Co., Ltd.
TWO:6572
|
Taiwan | NT$196.72 Million |
|
SavMobi Technology Inc.
PINK:SVMB
|
USA | $37.91 Million |
|
Tembaga Mulia Semanan Tbk
JK:TBMS
|
Indonesia | Rp76.22 Million |
Liability Composition Analysis (2018–2023)
This chart breaks down Bangkok Genomics Innovation Pcl's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bangkok Genomics Innovation Pcl's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bangkok Genomics Innovation Pcl (2018–2023)
The table below shows the annual total liabilities of Bangkok Genomics Innovation Pcl from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | ฿57.20 Million | +8.13% |
| 2022-12-31 | ฿52.90 Million | +37.46% |
| 2021-12-31 | ฿38.48 Million | -29.06% |
| 2020-12-31 | ฿54.25 Million | +148.91% |
| 2019-12-31 | ฿21.80 Million | -49.27% |
| 2018-12-31 | ฿42.96 Million | -- |